We describe the application of an intracellular antibody capture technology (IACT) as a generic in vivo selection procedure for isolating intracellular antibodies or ICAbs. IACT was applied to the de novo selection of functional ICAbs against the microtubule-associated protein TAU, found in neuro®brillary lesions of Alzheimer's disease brains. A panel of 17 different ICAbs was created which bind TAU inside cells and the epitopes recognized by the selected ICAbs have been determined by an in vivo epitope mapping procedure. Finally, sequence analysis showed that the IACT-derived ICAbs are characterized by a common signature of conserved amino acid residues, suggesting that the IACT naturally selects a sort of``captured consensus sequence'' for intracellular antibodies. The development of IACT, together with the possibility of scaling up in a high throughput and automated format, makes IACT a new enabling tool for target validation in functional genomics and global proteomics.
Introduction
Expression of antibodies as single chain Fv fragments (scFv) inside cells has been successfully used to ablate protein function. 1 Thus, intracellular antibodies (ICAbs) should play a role in human disease therapy by interfering with abnormal protein activity. Furthermore, in the context of functional genomics projects, ICAbs promise to be an important tool to knocking-out protein function inside the cell. In particular, technologies to achieve protein knock-out at a genomic scale would provide an essential tool to complement the growing efforts at building exhaustive protein interaction maps of cellular networks. 2 ± 5 In this context, however, the need for speed and high throughput requires the development of simple and robust methods to derive antibodies which function within cells, without the need for optimization of each individual ICAb. When antibodies are expressed in the cytoplasm, folding problems often occur. 6 The reducing conditions of the cytoplasm hinder the formation of the intra-domain disulphide bonds in the antibody variable domains. 7, 8 However, some scFv fragments tolerate the absence of this bond. 9, 10 No rules or predictions however can yet be made, about which antibodies will fold in the cell cytoplasm. We have recently provided the proof of principle of the intracellular antibody capture technology (IACT), an in vivo selection strategy for functional ICAbs, based on a two-hybrid approach. 11 IACT promises to be a robust procedure that should facilitate the isolation of speci®c ICAbs from complex mixtures. The technology has subsequently been used for the isolation of putative intracellular binders, but no functional characterization of the intracellular antibodies was provided.
12, 13 Here, we demonstrate that IACT can be effectively applied to the de novo selection of panels of functional ICAbs against diverse protein antigens and report the full characterization of a set of ICAbs selected against the microtubuleassociated protein (MAP) TAU, involved in Alzheimer's disease (AD). Our results demonstrate that antibodies suitable for intracellular expression are present in natural repertoires, which have been incorporated into phage libraries, 14, 15 and can be readily isolated with IACT, avoiding the need for any rational mutation strategy 16 ± 18 or molecular evolution approaches. 10, 19 Moreover, we found that ICAbs selected by IACT are characterized by a set of conserved residues that may de®ne the subset of antibodies that function ef®ciently inside cells. This intracellular consensus sequence (ICS) may allow the design of improved antibody libraries biased towards ICAbs.
Results

The intracellular antibody capture technology
The yeast two-hybrid strategy 20 can be used to isolate intracellular binders from sets of scFv that bind antigen in vitro. 11 We used IACT to undertake the de novo selection of ICAbs against a variety of different proteins of interest, including the human neuronal MAP protein TAU. TAU undergoes a pathological self-assembly into neuro®brillary tangles in the brain of AD patients, 21 whose mechanisms in vivo are unclear and intracellular antibodies may help in addressing these mechanisms. Figure 1 illustrates the overall design of the selection process that leads from a phage antibody library to a validated ICAb, expressed in mammalian cells. The chosen bait protein (i.e. TAU) is ®rst used to screen in vitro a library of scFv fragments displayed on phage 22 to generate a population of phages enriched for antigen-speci®c scFv. This in vitro panning step 1 ( Figure 1 ) is needed because of the difference between the complexity of the antibody phage library and the transformation ef®-ciency in yeast. We compared the results with one or two panning cycles in vitro, after which the antigen-enriched polyclonal population of scFv fragments is expressed as a``prey'' in the yeast antibody-antigen interaction assay 23 and challenged with the TAU antigen bait (step 2, Figure 1 ). The recovered scFv are subsequently functionally assessed in mammalian cells (step 3, Figure 1 ).
To isolate anti-TAU ICAbs using IACT, TAU fragment 151-421, which encompasses two prolinerich regions and the microtubule binding repeats, 24 was fused to maltose-binding protein (TAU-MBP), and used for two successive rounds of in vitro panning (step 1, Figure 1 ) with a non-immune library of human scFv fragments. 22 The diversity of the enriched ®rst and second-cycle libraries was assessed by PCR ®ngerprinting and sequence analysis of randomly isolated scFv fragments (N 100 for each cycle). After the ®rst cycle, 90 % of the scFv fragments were different, while after the second cycle only 13/100 different scFv fragments were found (Table 1) . TAU-reactive phages were revealed by phage ELISA: three and nine scFv fragments out of 96 randomly selected clones were TAU-positive, after one and two panning cycles, respectively (Table 1 ) and did not bind MBP or other proteins (Figure 2(a) ). The bulk DNA encoding for the ®rst and the second round polyclonal scFv-anti-TAU fragments was subcloned into the prey vector VP16AD, yielding two libraries (anti-TAU/VP16AD-I and anti-TAU/VP16AD-II), consisting of 2.2 Â 10 6 and of 6 Â 10 4 clones, respectively. These sub-libraries were challenged in yeast against the TAU bait, fused to lexA DNA binding domain (lexA-151-422TAU). Transformants were selected for histidine prototropy and 10 5 yeast transformants were screened for LacZ activity. 23 Plasmid DNA was isolated from 100 strong blue colonies from each selection and analysed by ®ngerprinting, yielding 31 and ®ve different scFv fragments from ®rst and second round libraries, respectively (data not shown). These were individually tested in secondary yeast screening, yielding 17 and three anti-TAU ICAbs, respectively (Table 1, Figure 2 (b)). It is noteworthy that the three anti-TAU/VP16AD-II were also found in the pool of 17 anti-TAU ICAbs selected from the ®rst round library (data not shown). This demonstrates that performing only one round of enrichment in vitro, prior to the selection in yeast, yields a more complete repertoire of ICAbs. The speci®city of the selected ICAbs was con®rmed by co-transfection with other baits (data not shown). Four ELISApositive anti-TAU fragments, randomly chosen from the enriched phage library among those that reacted more positively against TAU, failed to bind TAU bait (lexA-151-422TAU) in yeast, con®rming that the in vivo selection procedure was indeed necessary (Figure 2 (a) right).
Three anti-TAU ICAbs were expressed in Escherichia coli as periplasmic proteins and shown to recognize speci®cally full-length TAU and two deletion mutants (151-421TAUMBP and 151-422TAUMBP) (Figure 2(c) ). ScFv fragments often show a propensity to aggregate 25 and aggregation of intracellularly expressed scFv fragments is often observed. 26 Gel ®ltration analysis of puri®ed ICAbs showed, for all three scFvs, a single peak elution pro®le, corresponding to the monomeric form, as compared to the chromatogram of an aggregating scFv (Figure 2(d) ). These data demonstrate the low aggregating propensity of the scFv fragments isolated by IACT. The af®nity constants of the isolated scFv for TAU were evaluated by equilibrium saturation analysis/competition ELISA and by surface plasmon resonance and found to be in the range between 100 nM and 350 nM (data not shown).
Functional assays of anti-TAU ICAbs in mammalian cells
The anti-TAU ICAbs were expressed in mammalian cells, as leaderless cytoplasmic proteins. 26 ± 28 They show a diffuse intracellular staining, typical of soluble cytoplasmic proteins (Figure 3 ), unlike the doughnut-like pattern shown by aggregating scFv fragments (scFvaD11 in Figure 3 ). The ability of the anti-TAU ICAbs to interact with TAU in mammalian cells was veri®ed by a re-location assay. The anti-TAU scFv fragments were equipped with a nuclear localization signal (NLS) and individually co-expressed in CHO cells together with the TAU antigen ( Figure 4 (a)). The soluble scFvR4
8 was used as a negative control. Sub-cellular localization studies showed that TAU has a diffuse cytoplasmic distribution when transfected alone (Figure 4 (a), top left) whereas each NLS-tagged scFv fragment, when expressed in the absence of antigen, is found in the nucleus (Figure 4 (a), top right). When TAU is co-expressed with the non-relevant NLS-scFvR4 (Figure 4 (a), bottom right) it remains localized in the cytoplasm (red staining), while the scFvR4 is found in the nucleus (green staining). By contrast, a predominantly nuclear staining for TAU antigen was observed after co-expression with the anti-TAU scFv fragments (Figure 4(a) , centre left, centre right, bottom left) indicating an NLS-scFvmediated re-location of antigen. For quanti®cation (Figure 4(b) ), co-transfected cells were subdivided in four groups, according to the pattern of double staining observed (described in Figure 4 (c)). The ®rst three groups correspond to a successful relocation event, due to an intracellular antigen-antibody interaction, while the fourth group indicates an independent location of antigen and antibody, i.e. no interaction. As shown in Figure 4 (c), all cells transfected with the anti-TAU ICAbs are classi®ed in one of the ®rst three groups, while all cells expressing the control ICAb R4 fall in the fourth group (no relocation). This demonstrates the ability of anti-TAU ICAbs to bind speci®cally the TAU antigen in vivo in mammalian cells.
Expression in neuronal cell lines showed that at least one of the anti-TAU ICAb inhibits neurotrophin-mediated neurite outgrowth 29 (unpublished results).
In vivo epitope mapping (IVEM) of anti-TAU ICAbs
The characterization of the epitopes recognized by the anti-TAU ICAbs, was determined by in vivo epitope mapping (IVEM) with IACT. A panel of deletion mutants of the TAU protein starting from Ile151 to various residues towards the C terminus The number of positive clones and the number of monoreactive clones are shown.
Genetic Selection for Intracellular Antibodies of TAU ( Figure 5(a) ) was fused to LexA domain, yielding a set of TAU fragment baits. Each bait was challenged with each of the 17 anti-TAU ICAbs. Figure 5 (b) shows the detailed results for three ICAbs (scFv fragments scFv no. 2, scFv no. 14 and scFv no. 52), showing, for instance, that Monomeric scFv is eluted at about 12 ml. As a representative example, the analytical gel ®ltration chromatogram of scFvaD11 shows the amount of dimeric and aggregated species that were eluted at about 10.5 ml. Immuno¯uorescence microscopy of the anti-151-422TAU scFv fragments transiently transfected in COS cells. Cyto-scFv no. 2, cyto-scFv no. 14 and cytoscFv no. 52 and the control aD11 were visualized under a¯uorescence microscope. Cells were reacted with the anti-myc tag antibody 9E10, 62 followed by incubation with an anti-FITC-conjugated anti-mouse (Vector). scFv no. 2 binds to an epitope between T403 and S412. The overall picture for the whole panel of ICAbs shows that three main regions of TAU (I151-K274, N368-E391, D402-S412) are recognized by the selected ICAbs.
Sequence analysis of anti-TAU ICAbs
The sequences of ICAbs selected with IACT (IACT set) were compared to those of a group of randomly selected scFv fragments from the input library (control set) (17 and 16 sequences, respectively). All VH domains in the IACT set are VH III 30,31 while 13 VL domains are kappa I and four are kappa IV. Also in the control set most of VH sequences are VH III (only one was VH II), re¯ect-ing a bias in the input library. The VL in the control group are kappa I (ten sequences) and lambda (six sequences, mostly from subgroup IV). The average homology between individual members within the control set was 69 % for VH and 59 % for VL domains. The average homology within the IACT set was higher, 85 % for the VH and 77 % for the VL domains. Alignment of the VH and VL sequences of the IACT set ( Figure 6 ) showed that, within this set, 76 amino acid residues in VH (including two from CDR 1, one from CDR 2 and one from CDR 3) and 48 in the VL domains are conserved. Conserved residues de®ne an intracellular consensus sequence (ICS) for this set of antibodies ( Figure 6) .
A``virtual consensus sequence'' can be de®ned from the antibody sequences in the Kabat database, generated from the most frequent amino acid at each position. 30, 31 The degree of homology of the ICS to Kabat consensus sequences compiled from the Kabat database 30, 31 was evaluated. All but two of the 76 conserved residues in the IACT VH set are equal to the most frequently found residue at this position, in the Kabat consensus sequence for human VH. The two positions that do not follow the Kabat consensus are occupied, nevertheless, by residues (Phe67 and Asn73) whose occurrence probability is only slightly lower than the highest (1), (2) and (3) are indicative of an interaction between TAU and the scFv.
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one, in the Kabat consensus (Val in H67 and Thr in H73). Comparison with human VH III family, showed that only Gln in H1 is not as frequently found as Glu at this position, in the corresponding Kabat consensus set, while there is a perfect match at all the other positions. For the light chain, 47 residues out of the 48 conserved residues in the IACT VL set match the corresponding residues in Kabat consensus sequence while all the 48 conserved residues match the most frequently found in Kabat consensus for human VK.
Altogether, this analysis allows us to de®ne an ICAb consensus (ICS), which is highly homologous to the consensus sequences for human VH and VL in the Kabat database and, in particular, to the Kabat consensus for human VHIII and VL K.
The same analysis was performed on a larger IACT database, with antibodies from different libraries and selected against different antigens, con®rming the concept of a captured consensus sequence (unpublished results).
Discussion
Intracellular antibodies can be used to ablate protein function, with different modes of action. 1 Protein knock-out can be exploited for gene therapy, for target identi®cation and validation in functional genomics, or to elicit antigen-speci®c cell killing. 32 Other applications include intracellular imaging 33, 34 and diagnostics. 35, 36 There is therefore the need for experimental strategies to isolate antibodies that are suitable for intracellular expression. Indeed, not all antibodies tolerate the reducing conditions of the cell cytoplasm. 7, 26 To overcome these limitations we proposed that intracellular antibodies could be selected on the basis of their ability to bind antigen intracellularly. 11 Building on that proof of principle, we now provide evidence for the de novo selection of a panel of intracellular antibodies against a protein antigen involved in human AD.
Our results demonstrate that a large number of ICAbs against a single protein antigen are indeed present in large repertoires and that validated ICAbs can be readily and ef®ciently isolated and used with no need of individual optimization or engineering. We have now been able to select validated ICAbs against a number of different proteins (M.V. and A.C., unpublished results).
Sequence analysis demonstrated that IACT selection yielded sequences that are highly homologous to the consensus sequences for human VH and VL de®ned from the Kabat database. The latter are virtual consensus sequences, in that they are generated from the most frequent amino acid at each position. IACT leads to the selection of a sub-population of antibodies that are naturally present, albeit at low frequency, in antibody repertoires, and that are more effective in an intracellular environment. In particular, our results show that a combination of VH III and V K frameworks is likely to be more effective in this cellular environment.
The number of conserved residues in the IACT set de®nes an intracellular consensus sequence (ICS). As the database on ICAb sequences selected with IACT grows, the number of the ICS residues might decrease, converging to a minimal ICS (G.S., M.V., A.M. and A.C., unpublished results). Our results support the view that the overall stability of an antibody domain is contributed by a widespread set of stabilizing interactions between resi- . Sequence alignments of the VH and VL domains of the anti-TAU scFvs. The hypervariable regions (bold) are de®ned as by Chothia and Lesk. 63 The conserved residues (intracellular consensus sequence, ICS) for VH and VL are listed below each set of sequences. Primers for ampli®cations of V domains are labelled in red.
dues. Consensus sequence engineering has been previously shown to lead to improved ICAbs on a case-by-case basis. 17, 37 Our results show that IACT naturally provides a robust, ef®cient and generic biological consensus sequence selection method, leading to a sort of``captured consensus''. It should be possible to construct input libraries based on captured consensus. This will allow us to bring the input library down to a size compatible with its direct transformation in yeast, while maintaining its full diversity, further facilitating and accelerating the selection of ICAbs to target proteins of interest.
The large panel of anti-TAU ICAbs provides a useful tool to study TAU function in neurodegenerating neurons and brains.
For many applications, it is desirable to have antibodies that bind to a given epitope of an antigen. Different approaches are available, all involving epitope mapping in vitro. 38 ± 41 We describe here a rapid in vivo epitope mapping method (IVEM), which may become the method of choice for mapping the epitopes of ICAbs selected with IACT, and should greatly accelerate the detection of critical epitopes in high throughput screens.
IACT could be used, in conjunction with the surface display of cDNA products on E. coli 42 or on lambda phage, 43, 44 to derive ICAbs directly from gene sequences, with minimal handling of the corresponding proteins. IACT provides a direct link to go from phage display antibody libraries 45 to gene function. The preselection of phage antibody libraries on antigen arrays 46, 47 may represent one viable possibility to provide a diverse but enriched input library to yeast.
The need for technologies that allow studies of protein function in a highly parallel and high throughput manner suggests our protein knockout technology as a rapid, low-cost and simple way to deal with the functional genomics bottlenecks. The ability of IACT to isolate validated ICAbs, to be used for the validation of therapeutic targets, will help in the cell-wide analysis of protein networks and provides a new enabling tool for functional genomics and global proteomics. ScFv fragments were subcloned into the plasmids pUC119CAT (kind gift from T.H. Rabbitts) between S®I/NotI restriction sites and between NcoI/NotI restriction sites of scFvexpress plasmids 27 All clones were sequenced, using the Epicentre Sequitherm Excel II kit (Alsbyte, Mill Valley, CA), with a Li-Cor 4000L automatic sequencer (Lincoln, NE).
Materials and Methods
Plasmids
Protein productions
TAU protein was puri®ed from BL21(DE3) bacterial cells (kind gift from M. Novak) as described. 53 The MBPfusion proteins were puri®ed by one-step af®nity puri®-cation for MBP as described. 52 
Selection of phage antibody library
A non-immune phage antibody library 22 was selected as described 54 with TAU 151-421MBP protein-coated immunotubes (Nunc, Rochester, NY) (10 mg/ml overnight). After the ®rst and the second cycle of selection, 96 scFv fragments from individual colonies were identi®ed by BstNI ®ngerprinting. DNA ®ngerprinting and sequencing of 20 clones from each library con®rmed that the diversity was maintained. The same clones were used in phage ELISA. 54 
Construction of an activation domain-fusion anti-421MBP scFv library
Phagemid DNA from the ®rst and the second round phage library was extracted (Qiagen midiprep kit) and scFv fragment DNA subcloned into S®I/NotI-cut pVP16. 55 The ligation mix was electroporated into electrocompetent DH5aF
H (Gibco BRL, Rockville, MD) and plated on LB/ampicillin (100 mg/ml) plates to obtain the AD-libraries.
Yeast strain and protocols
The AD-fusion anti-151-421TAU scFv libraries were transformed in L40 Saccharomyces cerevisiae 56 containing TAU 151-422/BTM116 bait plasmid following a modi®-cation of published methods: 23 90 % of the clones grown in the absence of histidine gave a strong reaction in the b-Gal assay; 100 individual AD-fusion scFv plasmids were isolated from segregated yeast cells as described. 23 
Plasmids were rescued in DH5aF
H E. coli and scFv inserts were identi®ed by PCR-BstNI ®ngerprinting and by sequencing as described. 54 The isolated AD-fusion scFv plasmids were co-transformed with the LexA-151-422TAU antigen bait vector into L40 yeast strain by a lithium acetate transformation protocol 57 ± 59 and preselected by using auxotrophic markers and the X-Gal lift assay.
Expression and purification of scFv fragments
The scFvs were expressed from the plasmid pUC119-CAT in HB2151 E. coli, grown at 30 C for four hours after induction with 0.5 mM IPTG and puri®ed using the Ni-NTA kit (Qiagen, Valencia, CA). After veri®cation of scFv purity by SDS-PAGE, scFv concentrations were quanti®ed using the bicinchoninic acid kit (Pierce).
Analytical gel filtration
Gel ®ltration was carried out on a Superdex 75 (HR 10/30) column (Amersham Pharmacia Biotech, UK) in PBS. The scFv fragments were injected at 50-200 mg/ml in a volume of 200 ml. The column was calibrated in the same buffer with molecular mass standards.
Cell lines, transfection and immunofluorescence analysis
COS simian ®broblasts were grown in DMEM with 10 % (v/v) fetal bovine serum and high glucose. Cells were transiently transfected by the DEAE-dextran method 49 and analysed 48 hours after the transfection. Anti-TAU MN7.51 hybridoma supernatant 60 was used at a 1:50 dilution. mAb anti-myc antibody 9E10 61 and polyclonal anti-myc (Clontech) were used at 1:50 and 1:40, respectively. Texas red-conjugated anti-mouse (1:50 dilution, Vector),¯uorescein goat anti-mouse conjugate (1:50 dilution, Vector) or anti-rabbit immunoglobulins uorescein-conjugate (1:50 dilution, Vector) were used as secondary antibodies. Nuclei were stained with the¯uor-escent dye DAPI (Boehringer Mannheim).
CHO (Chinese Hamster Ovary) cells were grown in DMEM with 10 % fetal bovine serum, high glucose and proline (17.2 mg/l ®nal concentration). CHO were transiently transfected by the FuGENE-6 transfection reagent (Roche) method according to the manufacturer's instructions and analysed 30-48 hours after the transfection.
Sequence analysis
Sixteen scFvs from the input library and 25 anti-TAU scFv selected with IACT were sequenced, using the Epicentre Sequitherm Excel II kit (Alsbyte, Mill Valley, CA), on a Li-Cor 4000L automatic sequencer (Lincoln, NE). Sequence alignments and analysis were carried out as described by Kabat. 30, 62 
